Article Text

Download PDFPDF
Should the new pneumococcal vaccine be used in high-risk children?
  1. A Finn1,
  2. R Booy3,
  3. R Moxon4,
  4. M Sharland2,
  5. P Heath2
  1. 1Institute of Child Health, University of Bristol, UK
  2. 2St George's Vaccine Institute and St George's Hospital Medical School, Tooting, London, UK
  3. 3Royal London Hospital, Whitechapel, London, UK
  4. 4Oxford Vaccine Group, Oxford, UK
  1. Correspondence to:
    Prof. A Finn, Institute of Child Health, UBHT Education Centre, Level 6, Upper Maudlin St, Bristol BS2 8AE, UK;
    Adam.Finn{at}bristol.ac.uk

Abstract

A new conjugate 7-valent vaccine to prevent pneumococcal infection (Prevenar, Wyeth) has recently received a European licence for use in young healthy children. The vaccine is not currently included in the universal immunisation schedule in the UK or elsewhere in Europe, although it is being used widely in the USA. Its availability for purchase raises the question whether paediatricians should consider using it in high risk children, including those for whom the polysaccharide 23-valent vaccine was previously recommended, until (or unless) it is introduced into general use—indeed the Chief Medical Officer for England and Wales has recently made a recommendation regarding such children aged less than 2 years. We review the evidence concerning use of the vaccine in such children and make suggestions as to how the vaccine may be used while further information is collected.

  • pneumococcal vaccine
  • Prevenar
  • AAP, American Academy of Paediatrics
  • CSF, cerebrospinal fluid
  • SCD, sickle cell disease

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

Linked Articles

  • Atoms
    Harvey Marcovitch